KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) Cost of Revenue (2016 - 2025)

Resmed (RMD) has disclosed Cost of Revenue for 17 consecutive years, with $528.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue changed 0.44% year-over-year to $528.5 million, compared with a TTM value of $2.1 billion through Dec 2025, up 2.27%, and an annual FY2025 reading of $2.1 billion, up 3.02% over the prior year.
  • Cost of Revenue was $528.5 million for Q4 2025 at Resmed, up from $514.8 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $535.4 million in Q2 2025 and bottomed at $310.6 million in Q1 2021.
  • Average Cost of Revenue over 5 years is $462.1 million, with a median of $494.9 million recorded in 2023.
  • Peak annual rise in Cost of Revenue hit 42.02% in 2021, while the deepest fall reached 2.88% in 2021.
  • Year by year, Cost of Revenue stood at $390.6 million in 2021, then grew by 16.25% to $454.0 million in 2022, then increased by 15.58% to $524.8 million in 2023, then rose by 1.15% to $530.8 million in 2024, then dropped by 0.44% to $528.5 million in 2025.
  • Business Quant data shows Cost of Revenue for RMD at $528.5 million in Q4 2025, $514.8 million in Q3 2025, and $535.4 million in Q2 2025.